

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



撥康視云™

Cloudbreak Pharma

CLOUDBREAK PHARMA INC.

撥康視雲製藥有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2592)

DATE OF BOARD MEETING

The board (the “**Board**”) of directors (the “**Directors**”) of Cloudbreak Pharma Inc. (the “**Company**”; together with its subsidiaries, the “**Group**”) hereby announces that a meeting of the Board will be held on Monday, 30 March 2026 for the purposes of, among other matters, considering and approving the audited annual results of the Group for the year ended 31 December 2025 for publication and the recommendation of the payment of a final dividend, if any.

By order of the Board

Cloudbreak Pharma Inc.

Dr. NI, Jinsong

Chairman, Executive Director and Chief Executive Officer

Hong Kong, 18 March 2026

As at the date of this announcement, the Board comprises: (i) Dr. Ni Jinsong, Mr. Dinh Son Van, Dr. Yang Rong as executive Directors; (ii) Dr. Li Jun Zhi, Mr. Cao Xu and Mr. Xia Zhidong as non-executive Directors; and (iii) Ms. Nie Sijiang, Mr. Ma Yiu Ho Peter, Mr. Lee Alex Jao Jang as independent non-executive Directors.

* For identification purpose only